Jean-Paul Clozel, Idorsia CEO (AP Images)
Idorsia's Fabry disease program flops a PhIII study, leaving its future unclear
A top program for Swiss biotech Idorsia faces a murky future after flunking a Phase III test.
Idorisa’s drug candidate for Fabry disease, known as …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
